2022 World Conference on Lung Cancer (ePosters)-EP08.02-058. A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib

EP08.02-058. A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience

Pdf Summary

A case series of patients with KRAS G12C mutation treated with sotorasib in Croatia was conducted. Sotorasib is a targeted therapy recently approved for this specific mutation. Four patients were treated with sotorasib between May and December 2021, all of whom had previously received immune checkpoint inhibitors. The patients' ages ranged from 47 to 74, and they were all ex-smokers with a median pack/years of 20. Sotorasib was administered orally at a dose of 960 mg once daily.<br /><br />The results showed that two patients had a partial response to the treatment, two had stable disease, and one patient experienced disease progression after 5 months. One patient had no side-effects and continued to take the standard dose for 6 months with a partial response. However, three patients experienced hepatic side effects, including alanine aminotransferase and aspartate aminotransferase increase, which were categorized as grade 2-3 according to CTCAE. The side effects occurred between 4 and 12 weeks after starting sotorasib. The treatment was paused for a median of 14 days and then resumed with a decreased dose of 480 mg once daily. Two of the patients did not experience further liver toxicities, while one patient had grade 3 elevation in liver enzymes, requiring another treatment pause until recovery to grade 1. Sotorasib was then continued with a further dose reduction to 240 mg for 8 weeks before being permanently discontinued due to disease progression.<br /><br />In conclusion, sotorasib showed clinical efficacy regardless of the treatment line, but most patients experienced side-effects that required dose reductions. Despite the dose reductions, the drug's efficacy remained stable. However, further data from larger patient cohorts are needed to validate these findings.

Asset Subtitle

Fran Seiwerth

Meta Tag

Speaker Fran Seiwerth

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

KRAS G12C mutation

sotorasib

targeted therapy

Croatia

case series

immune checkpoint inhibitors

partial response

stable disease

disease progression

side effects